AR002717A1 - Compuestos de beta-alanina y sus sales farmaceuticamente aceptables, procedimiento para prepararlos, composiciones farmaceuticas que los contienen ymetodos para tratar trastornos cardiovasculares tales como los causados por la formacion de trombosis, trombocitosis, reemplazo de valvulas o implantes - Google Patents
Compuestos de beta-alanina y sus sales farmaceuticamente aceptables, procedimiento para prepararlos, composiciones farmaceuticas que los contienen ymetodos para tratar trastornos cardiovasculares tales como los causados por la formacion de trombosis, trombocitosis, reemplazo de valvulas o implantesInfo
- Publication number
- AR002717A1 AR002717A1 ARP960101780A AR10178096A AR002717A1 AR 002717 A1 AR002717 A1 AR 002717A1 AR P960101780 A ARP960101780 A AR P960101780A AR 10178096 A AR10178096 A AR 10178096A AR 002717 A1 AR002717 A1 AR 002717A1
- Authority
- AR
- Argentina
- Prior art keywords
- trombosis
- alkylene
- pharmaceutical compositions
- compositions containing
- thrombosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La invención de refiere a compuestos de beta-alanina y sus sales farmacéuticamente aceptables, procedimiento para prepararlos, composicionesfarmacéuticas que los contienen y métodos para tratar trastornos cardiovascularesta les como los causados por la formación de trombosis,trombocitosis, reemplazo de válvulas o implantes de fórmula (I), donde R1 es piperidilo, tetrahidropiridilo, aczetidinilo, tetrahidroisoquinolilo,protegidos en el amino o nó; R2 es carboxi ocarb oxi protegido; A1 es alquileno, alcanoíl-ilideno, alquileno ciclo alquileno o arileno; A2 esalquileno sustituidos o nó o arileno; el heterociclo indicado en la fórmula es piperidindiilo o tetrahidroisoquinolindiilo, y m es un enteroque va le 0 ó 1;con la condición de que: cuando R1 es piperidilo; A1 es alquileno; y A2 es alquileno sustituido o nó salvo un grupo heteromonocíclico de 5 ó 6 miembrosque tiene 1 ó 2 átomos de oxígeno y de 1 a 3 átomos de nitrógeno, que puede tener uno o más sustituyentes. Estos compuestos son antagonistas de laglicoproteina IIB/IIIa, inhibidores de la agregación de las plaquetas e inhibidores de la vinculación del fibrinógeno a las plaquetas de la sangre. Seun procedimientopara la pr eparación de los mismos, composiciones farmacéuticas que los contienen y a un método para la prevención y/o tratamiento de lasenfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9505437.5A GB9505437D0 (en) | 1995-03-17 | 1995-03-17 | New compound |
GBGB9524266.5A GB9524266D0 (en) | 1995-11-28 | 1995-11-28 | New compound |
Publications (1)
Publication Number | Publication Date |
---|---|
AR002717A1 true AR002717A1 (es) | 1998-04-29 |
Family
ID=26306701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101780A AR002717A1 (es) | 1995-03-17 | 1996-03-15 | Compuestos de beta-alanina y sus sales farmaceuticamente aceptables, procedimiento para prepararlos, composiciones farmaceuticas que los contienen ymetodos para tratar trastornos cardiovasculares tales como los causados por la formacion de trombosis, trombocitosis, reemplazo de valvulas o implantes |
Country Status (10)
Country | Link |
---|---|
US (1) | US6384028B1 (es) |
EP (1) | EP0869944A1 (es) |
JP (1) | JPH11502224A (es) |
KR (1) | KR19980703107A (es) |
AR (1) | AR002717A1 (es) |
AU (1) | AU4954296A (es) |
CA (1) | CA2215106A1 (es) |
IL (1) | IL117495A (es) |
TW (1) | TW406079B (es) |
WO (1) | WO1996029309A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010051730A1 (en) * | 1993-09-22 | 2001-12-13 | Fujisawa Pharmaceutical Co., Ltd. | Beta-alanine derivative and a process for the preparation thereof |
WO1997033869A1 (en) * | 1996-03-13 | 1997-09-18 | Fujisawa Pharmaceutical Co., Ltd. | N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist |
SI0923555T1 (en) * | 1996-05-01 | 2005-10-31 | Ortho-Mcneil Pharmaceutical, Inc. | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders |
JP4328387B2 (ja) * | 1996-05-01 | 2009-09-09 | オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド | 血栓形成疾患の処置のためのピロリジン、ピペリジン及びヘキサヒドロアゼピンのカルボキサミド誘導体 |
US6066651A (en) | 1997-10-29 | 2000-05-23 | Ortho-Mcneil Pharmaceutical, Inc. | Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders |
AU769718B2 (en) * | 1998-10-12 | 2004-02-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing beta-alanine derivative |
AUPP646598A0 (en) * | 1998-10-12 | 1998-11-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing alpha-alanine derivative |
AUPQ570100A0 (en) | 2000-02-17 | 2000-03-09 | Fujisawa Pharmaceutical Co., Ltd. | Beta-alanine derivatives and their use as receptor antagonists |
CA2492035A1 (en) | 2002-07-11 | 2004-01-15 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
WO2005019177A1 (en) * | 2003-08-14 | 2005-03-03 | Icos Corporation | Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof |
WO2005079863A1 (ja) * | 2004-02-25 | 2005-09-01 | Astellas Pharma Inc. | 血栓造影剤 |
RU2009136330A (ru) | 2007-03-01 | 2011-04-10 | Янссен Фармацевтика Н.В. (Be) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора |
ES2621379T3 (es) | 2011-08-17 | 2017-07-03 | Piramal Imaging Sa | Compuestos para la unión a la glicoproteína IIb/IIIa específica de las plaquetas y su utilización para la formación de imágenes de trombos |
JP2016508507A (ja) | 2013-02-12 | 2016-03-22 | バイエル・ファルマ・アクティエンゲゼルシャフト | 血小板特異的糖タンパク質IIb/IIIaに結合するための金属キレート化合物 |
KR102548998B1 (ko) | 2020-03-31 | 2023-06-29 | 재단법인 아산사회복지재단 | 혈전영상을 위한 방사성의약품 및 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053392A (en) * | 1989-12-01 | 1991-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors |
CA2037153A1 (en) * | 1990-03-09 | 1991-09-10 | Leo Alig | Acetic acid derivatives |
US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
DK0669912T3 (da) * | 1993-09-22 | 2002-03-04 | Fujisawa Pharmaceutical Co | N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister |
DE69426602T2 (de) * | 1993-10-19 | 2001-08-30 | Sumitomo Pharma | 2,3-diaminopropionsäurederivate |
US5770575A (en) * | 1994-03-16 | 1998-06-23 | Ortho Pharmaceutical Corporation | Nipecotic acid derivatives as antithrombotic compounds |
-
1996
- 1996-03-14 KR KR1019970706509A patent/KR19980703107A/ko not_active Application Discontinuation
- 1996-03-14 US US08/894,795 patent/US6384028B1/en not_active Expired - Fee Related
- 1996-03-14 IL IL11749596A patent/IL117495A/en not_active IP Right Cessation
- 1996-03-14 WO PCT/JP1996/000643 patent/WO1996029309A1/en not_active Application Discontinuation
- 1996-03-14 JP JP8528273A patent/JPH11502224A/ja not_active Ceased
- 1996-03-14 CA CA002215106A patent/CA2215106A1/en not_active Abandoned
- 1996-03-14 AU AU49542/96A patent/AU4954296A/en not_active Abandoned
- 1996-03-14 EP EP96906017A patent/EP0869944A1/en not_active Withdrawn
- 1996-03-15 AR ARP960101780A patent/AR002717A1/es not_active Application Discontinuation
- 1996-03-16 TW TW085103157A patent/TW406079B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL117495A0 (en) | 1996-07-23 |
CA2215106A1 (en) | 1996-09-26 |
EP0869944A1 (en) | 1998-10-14 |
IL117495A (en) | 2002-05-23 |
JPH11502224A (ja) | 1999-02-23 |
TW406079B (en) | 2000-09-21 |
KR19980703107A (ko) | 1998-10-15 |
WO1996029309A1 (en) | 1996-09-26 |
AU4954296A (en) | 1996-10-08 |
US6384028B1 (en) | 2002-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR002717A1 (es) | Compuestos de beta-alanina y sus sales farmaceuticamente aceptables, procedimiento para prepararlos, composiciones farmaceuticas que los contienen ymetodos para tratar trastornos cardiovasculares tales como los causados por la formacion de trombosis, trombocitosis, reemplazo de valvulas o implantes | |
MX9206474A (es) | Derivados de n-fenilalanil y n-fenilgliclil del dipeptido del acido l-azetidina 2-carboxilico y aldheido de l-arginina, proceso para su preparacion y composicion farmaceutica que los contiene | |
AR039566A1 (es) | Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion | |
BR9609151A (pt) | Composto éster de prodroga método para prevenção ou tratamento de trombose composição farmacêutica método de inibição de agregação de plaquetas de sangue método de tratamento de desordens tromboemólicas método para tratamento de trombose método de tratamento de artrite reumatóide processo para preparação de um composto e método de administração de um composto | |
PE109698A1 (es) | Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su preparacion | |
GR3034682T3 (en) | Novel medical use for tachykinin antagonists. | |
ES2150489T3 (es) | 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas. | |
AR003453A1 (es) | Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores | |
AR033306A1 (es) | Compuestos | |
ES2137998T3 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
MXPA01004256A (es) | N-arilamidas del acido antranilico y del acido tioantranilico. | |
DK0687268T3 (da) | Spiroazacykliske derivater som substans P-antagonister | |
GEP20032954B (en) | Heterocyclic Inhibitors of P38 | |
AR039127A1 (es) | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento | |
AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
UY25804A1 (es) | Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3 | |
DE60041763D1 (de) | Inhibitoren von c-jun n-terminal kinasen (jnk) | |
BR9916491A (pt) | 4-(aminometil)-piperidina benzamidas para tratamento de distúrbios gastrintestinais | |
CO5011105A1 (es) | Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion | |
IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
DE602004020685D1 (de) | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon | |
AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
DE68923151T2 (de) | Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen. | |
UY26564A1 (es) | Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos | |
FR2586679B1 (fr) | Composes heterocycliques, procedes pour leur preparation, et compositions pharmaceutiques les contenant pour inhiber l'enzyme de conversion de l'angiotensine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |